American Society of Hematology

Session Previews

Focus on Leukemia
Speaker: Anjali Advani, MD

Anjali Advani, MD, discusses exciting updates in leukemia, including newly approved drugs (blinatumomab) and drugs in the pipeline (inotuzumab). Leukemia is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM), which is structured in a “How I Treat” format that provides an ideal learning experience for physicians who treat leukemia. The meeting’s expert speakers discuss specific patient cases, present cutting-edge scientific data, and provide insight into how new treatments can be incorporated upfront.

Focus on MDS 
Speaker: Amy DeZern, MD

Amy DeZern, MD, discusses exciting updates in myelodysplastic syndromes (MDS), including new drugs in the pipeline such as targeted agents and spliceosome modulators. MDS is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM). MHM is structured in a “How I Treat” format, which is extremely beneficial to physicians because it takes a true clinical scenario and offers insight from an expert who treats the disease on a regular basis into how novel testing and the novel potential therapeutic pathways can be incorporated to improve diagnosis and treatment.

Focus on Lymphoma 
Speaker: John Leonard, MD, and Jonathan Friedberg, MD, MMSc

John P. Leonard, MD, and Jonathan W. Friedberg, MD, discuss exciting updates in lymphoma, including newly approved drugs (e.g., obinutuzumab for chronic lymphocytic leukemia) and new data that may have practice-changing implications for various lymphoma subtypes. Lymphoma is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM). MHM is structured in a “How I Treat” format, which focuses not only on what the data show but on how to apply the data to optimally treat patients. The 2017 ASH Meeting on Hematologic Malignancies will also feature a talk that focuses on which tests to run to diagnose and follow patients across the non-Hodgkin lymphoma spectrum.

Focus on MPN
Speaker: Ruben Mesa, MD

Ruben A. Mesa, MD, discusses exciting updates in myeloproliferative neoplasms (MPN), including new JAK-2 inhibitors that might influence treatment and the emergence of precision medicine. MPN is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM), a practical and practice-focused meeting that offers an ideal learning experience for physicians who treat myeloproliferative neoplasms. The meeting’s expert speakers discuss challenging patient cases, present new data, and provide insight into how physicians can apply new treatments to patients the very next day.

Focus on Myeloma
Speaker: S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, discusses exciting advances in myeloma, including new drugs in the pipeline (e.g., selinexor and venetoclax). Myeloma is one of the core malignancies covered at the ASH Meeting on Hematologic Malignancies (MHM), a practical and practice-focused meeting that offers an ideal learning experience for physicians who treat hematologic malignancies. The meeting’s expert speakers discuss challenging patient cases, present new data, and provide insight into how physicians can apply new treatments to patients the very next day.

back to top